Friday Nov 08, 2024
FT
Friday Nov 08, 2024
Monday, 27 July 2015 00:00 - - {{hitsCtrl.values.hits}}
Lupin Ltd., India’s fourth-largest drugmaker by sales, said it had agreed to buy privately-held generics company Gavis for $880 million to strengthen its presence in its largest market, the United States.
The deal, which is cash-free and debt-free, widens the company’s pipeline in dermatology and controlled substance products, Lupin said in a statement.
The company’s shares were down 6% at Rs. 1,723 as of 3:06 p.m. on the NSE.
